Hepatitis B Immunity Guidelines

Definition and Testing

• The CDC defines protective immunity against hepatitis B as an anti-HBs level of ≥10 mIU/mL, which can be detected using a quantitative assay such as ELISA 1
• Testing for anti-HBs should be performed 1-2 months after the final dose of the vaccine series to determine protective immunity 2, 3
• An anti-HBs level of ≥10 mIU/mL indicates protective immunity, and the person is considered immune 3, 4

Special Populations

• Immunocompetent individuals who achieve anti-HBs ≥10 mIU/mL after completing the primary vaccine series have long-term protection and do not need further periodic testing or booster doses 2, 4
• Healthcare personnel should be tested for anti-HBs upon hire or matriculation if they have documentation of complete vaccination, and those with anti-HBs <10 mIU/mL need additional vaccine doses 1, 5
• Hemodialysis patients require annual anti-HBs testing, with booster doses administered when levels decline to <10 mIU/mL 5
• Immunocompromised persons may need annual anti-HBs testing to assess concentrations 2, 5
• Infants born to HBsAg-positive mothers require specific revaccination protocols if anti-HBs is <10 mIU/mL after the primary series 1, 6

Clinical Considerations

• Different laboratory assays have different cutoff values, so the reported anti-HBs level may vary depending on which assay is used, and the package insert of the specific test should be referred to determine the actual protective level 1, 6
• The CDC recommends against routinely retesting or giving booster doses to healthy immunocompetent individuals whose anti-HBs has declined below 10 mIU/mL after initially responding to vaccination 5
• The CDC also recommends against confusing the protective threshold (≥10 mIU/mL) with assay-specific cutoff values that may differ between laboratories 1, 7

Hepatitis B Immunity Guidelines for Healthcare Workers

Protective Antibody Threshold

• The CDC and ACIP define protective immunity against hepatitis B as an anti‑HBs level ≥ 10 mIU/mL; a titer of 30 mIU/mL therefore confirms adequate immunity and eliminates the need for repeat vaccination. 8

Duration of Protection

• Vaccine responders maintain protection against symptomatic and chronic HBV infection for ≥ 22 years, even as circulating antibody levels naturally decline over time. 8

Post‑Exposure Management

• Healthcare workers who have documented immunity (anti‑HBs ≥ 10 mIU/mL) do not require post‑exposure prophylaxis, additional serologic testing, or extra vaccine doses after occupational exposures. 9

Immune Memory

• Immunocompetent individuals retain hepatitis B protection through cellular immune memory even when anti‑HBs titers fall below 10 mIU/mL. 8
• The majority of vaccine responders exhibit a rapid anamnestic (memory) response to a hepatitis B vaccine challenge despite low or undetectable antibody levels. 8

Occupational Practice

• With a protective anti‑HBs titer, healthcare workers may continue clinical duties without restrictions and are considered immune. 9

Monitoring in Immunocompromised Situations

• If a worker becomes immunocompromised (e.g., HIV infection or immunosuppressive therapy), reassessment of hepatitis B immunity is warranted. 8

Confirming Hepatitis B Vaccine Immunity

Testing Recommendations

• Order a quantitative anti‑HBs assay (e.g., ELISA) to measure hepatitis B surface antibody levels; a single test is sufficient when the vaccine series is documented and no additional risk factors are present. – CDC recommendation 10

• Perform the anti‑HBs test 1–2 months after the final vaccine dose; testing earlier may yield falsely low results because the peak antibody response has not yet occurred. – CDC recommendation 10

• Testing later than 6 months after vaccination is acceptable, but declining antibody levels at that time do not necessarily indicate loss of immunity. – CDC recommendation 11

Interpretation of Results

• Anti‑HBs ≥ 10 mIU/mL indicates immunity and protection; immunocompetent individuals require no further testing or booster doses. – CDC recommendation 10

• Anti‑HBs < 10 mIU/mL defines a non‑responder who remains susceptible to infection. – CDC recommendation 10

• For a non‑responder, give one booster dose of hepatitis B vaccine immediately and repeat anti‑HBs testing 1–2 months later. – CDC recommendation 10

• If anti‑HBs remains < 10 mIU/mL after the booster, complete a full second 3‑dose series (0, 1, 6 months) and retest 1–2 months after the final dose. – CDC recommendation 10

• If, after a total of six vaccine doses, anti‑HBs is still < 10 mIU/mL, test for HBsAg and anti‑HBc to exclude chronic hepatitis B infection. – CDC recommendation 10

Timing of Post‑Vaccination Testing

• Optimal testing window: 1–2 months post‑final dose. – CDC recommendation 10

• Testing beyond 6 months is permissible but may reflect natural antibody waning rather than true loss of immunity. – CDC recommendation 11

Populations Requiring Routine Post‑Vaccination Testing

• Healthcare workers and public‑safety personnel with exposure risk, hemodialysis patients, HIV‑infected or otherwise immunocompromised persons, and sexual partners of HBsAg‑positive individuals should undergo post‑vaccination anti‑HBs testing. – CDC recommendation 10

Serologic Markers (Interpretation)

These definitions are based on CDC guidance.* – CDC recommendation 12

Management of Immunocompromised Patients

• Annual anti‑HBs testing is advised for immunocompromised individuals (e.g., HIV infection, chemotherapy, hemodialysis, transplant recipients). – CDC recommendation 10

• Booster doses should be administered when anti‑HBs levels fall below 10 mIU/mL in this population. – CDC recommendation 10

• Higher initial vaccine doses (40 µg rather than the standard 10–20 µg) may be required to achieve protective immunity in immunocompromised patients. – CDC recommendation 12